Macugen and Levofloxacin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Macugen (pegaptanib sodium) and Levofloxacin (levofloxacin; sodium chloride). Common drug interactions include myocardial infarction among females and cerebral infarction among males.

The phase IV clinical study analyzes what interactions people have when they take Macugen and Levofloxacin. It is created by eHealthMe based on reports of 39 people who take the same drugs from the FDA, and is updated regularly.

What is Macugen?

Macugen has active ingredients of pegaptanib sodium. eHealthMe is studying from 615 Macugen users. Check the latest studies of Macugen.

What is Levofloxacin?

Levofloxacin has active ingredients of levofloxacin; sodium chloride. It is often used in sinusitis. eHealthMe is studying from 16,335 Levofloxacin users. Check the latest studies of Levofloxacin.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 26, 2026

39 people who take Macugen and Levofloxacin together, and have interactions are studied.

Macugen and Levofloxacin drug interactions.

What are the common drug interactions of Macugen and Levofloxacin, by gender? *:

female:

  1. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  2. Blood pressure decreased
  3. Cardiac failure
  4. Optic ischaemic neuropathy (optic nerve damage due to lack of blood supply)
  5. Retinal haemorrhage (bleeding from retina)
  6. Ventricular hypokinesia (muscle of one's heart does not contract as much as most peoples' hearts do)
  7. Chest pain
  8. Coronary artery occlusion (complete obstruction of blood flow in a coronary artery)
  9. Cough
  10. Dyspnoea (difficult or laboured respiration)

male:

  1. Cerebral infarction (less blood supply to brain resulting tissue damage)
  2. Endophthalmitis (inflammation of the internal coats of the eye)
  3. Conjunctivitis allergic (inflammation of the conjunctiva due to allergy)
  4. Eye pruritus (eye itching)
  5. Retinal detachment (a disorder of the eye in which the retina peels away from its underlying layer of support tissue)
  6. Alanine aminotransferase increased
  7. Aspartate aminotransferase increased
  8. Blood alkaline phosphatase increased
  9. Blood bilirubin increased
  10. Drug effect decreased

What are the common drug interactions of Macugen and Levofloxacin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Cerebral infarction (less blood supply to brain resulting tissue damage)
  2. Vitreous haemorrhage (intraocular (inside the eye) bleeding)
  3. Retinal detachment (a disorder of the eye in which the retina peels away from its underlying layer of support tissue)
  4. Blood pressure systolic increased
  5. Optic ischaemic neuropathy (optic nerve damage due to lack of blood supply)
  6. Retinal vein occlusion (a blockage of the small veins that carry blood away from the retina)
  7. Ventricular hypokinesia (muscle of one's heart does not contract as much as most peoples' hearts do)
  8. Asthenopia (eyestrain-tiredness of the eyes caused by prolonged close work by a person with an uncorrected vision problem)
  9. Conjunctivitis allergic (inflammation of the conjunctiva due to allergy)
  10. Eye pruritus (eye itching)

What are the existing conditions these people have? *

  1. Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 20 people, 51.28%
  2. Age-Related Macular Degeneration: 8 people, 20.51%
  3. Maculopathy (a condition or disease of the macula, the small spot in the retina where vision is keenest): 4 people, 10.26%
  4. Polypoidal Choroidal Vasculopathy (polyp-like sub-retinal pigment epithelium vascular abnormalities predominantly found in the macula and peripapillary region): 3 people, 7.69%
  5. Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Macugen and Levofloxacin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Macugen and Levofloxacin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Macugen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Levofloxacin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Macugen and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Levofloxacin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on pegaptanib sodium and levofloxacin; sodium chloride (the active ingredients of Macugen and Levofloxacin, respectively), and Macugen and Levofloxacin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: